chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Body rash,hives, facial flushing, and chest heaviness throat tightness, blurred vision, dizziness.  10/15/2007 Corrected DOB updated in database.  MR received for ER visit 10/01/2007 for DX:  Allergic reaction to Td. Pt presented to ER with c/o blurred vision, weakness, tingling, diffuse erythema and throat tightness, SOB, wheezing and chest pain. Txd with steroids and Benadryl with full recovery.
Little headache; Arm was a little sore; Slight chills; General aches and pains; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm was a little sore), CHILLS (Slight chills), MYALGIA (General aches and pains) and HEADACHE (Little headache) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Apr-2021, the patient experienced PAIN IN EXTREMITY (Arm was a little sore), CHILLS (Slight chills) and MYALGIA (General aches and pains). On 27-Apr-2021, the patient experienced HEADACHE (Little headache). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at a dose of 1 dosage form. At the time of the report, PAIN IN EXTREMITY (Arm was a little sore), CHILLS (Slight chills), MYALGIA (General aches and pains) and HEADACHE (Little headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided. Treatment information include Tylenol and ice pack. Action taken with mRNA-1273 in response to the event was not applicable.
Patient 1: found to be non-immune to VZV, despite receiving immunization at 11 years of age; none of the patients developed symptoms of vaccine related viral illness; This literature marketed report has been received from the authors of the published article, titled as stated below referring  a 11 year old female patient. The patient's concurrent conditions included dilated cardiomyopathy and heart failure. Information regarding the patient's pertinent medical history and concomitant medications was not provided by the authors.  On an unspecified date, the patient was vaccinated with varicella virus vaccine live (Oka/Merck) (manufacturer unknown) for prophylaxis (strength, dose, route of administration, frequency, lot number and expiration date were not provided).  On an unspecified date, at the age of 12 years the patient was going to underwent on an orthotopic heart transplantation (OTH) for her dilated cardiomyopathy and heart failure. Her pre-transplant infectious diseases evaluation was unremarkable except as that she was found to be immune to measles mumps and rubella but was not immune to varicella zoster virus (VZV) despite being vaccinated previously (vaccination failure). She was therefore given a second dose of varicella virus vaccine live (Oka/Merck) (manufacturer unknown), and eight days later she underwent the OTH surgery. It was reported that the patient did not develop any symptoms of vaccine related viral illness.   At the time of reporting, the outcome of vaccination failure was unknown.   The causal relationship between the vaccination with varicella virus vaccine live (Oka/Merck) (manufacturer unknown) and vaccination failure was considered to be related.   This is one of three reports received from the same literature (2107USA005480, 2107USA005481 and 2107USA002514) Sender's Comments:  US-009507513-2107USA005480: US-009507513-2107USA005481:
HEADACHE, CHILLS, NIGHT SWEATS, RUNNY NOSE, TEMPERATURE
After receiving the Menactra vaccine in clinic on 2/29/16 (2nd dose), patient left the clinic with her mother around 5PM.  Her mother stated that patient had a seizure in the car about 10 minutes after leaving the clinic, with patient's arm extended and patient out of it for no more than 30 seconds.  Mother drove back to the clinic and told MD about the seizure.  MD examined the patient who was doing fine after the seizure.  MD called the patient's home at 0810 the next morning and spoke with patient's father.  Father reported that there was no additional seizure or other adverse effects overnight.  Patient recovered.
Pediatric dose was given to adults mistakenly; Moderna COVID-19 vaccine administered to patients post temperature excursion; Poor quality vaccine administered; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patients post temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patients post temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patients post temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patients post temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered).    This case contains information for the 45 of 104 patients described by the reporter.  No concomitant medication was reported.  It was reported that there was a temperature excursion between 26-May-2022 to 30-Sep-2022 and lot AR5186C was affected between 08-Sep-2022 to 27-Sep-2022. AR5186C was previously reported. Pediatric dose was given to adults mistakenly and were reported to CDPH, VAERS, CAIR and each patient that received the error dose, with instructions to re-vaccinate 2 months from the initial error dose. 051B22A was kept in the freezer upon receipt of shipment on 01-Aug-2022 and individual vials were put in the refrigerator on the day of use.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-669791 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-669791:Master case
patient had a little headache and fatigue which she said she's ok with.  patient also stated she had random smell, particularly COFFEE which she does not drink or have.
Undetected for months until recently in October noticed actinic keratosis due to itching discomfort and raised dead skin patient removed exposing small raw 2 cm spot. Initial reaction had been soreness and swelling subsiding after a week. Never noticed any red patch due to injection site location on right upper deltoid.
This spontaneous report was received from a pharmacist via a company representative referring to a patient of unknown age and gender. The patient's medical history and concurrent conditions were unknown. On 08-SEP-2016, the patient was administered simultaneously PNEUMOVAX 23 (lot number, expiration date, concentration, dose, frequency and route of administration were unknown) and ZOSTAVAX (lot number, expiration date, concentration, dose, frequency and route of administration were unknown). Information regarding concomitant medications were unknown. On 09-SEP-2016, the patient experienced flu like symptoms, cold chills, cold and nausea. At the time of the report, the outcome of flu like symptoms, cold chills, cold and nausea was unknown. The causality between PNEUMOVAX 23 and ZOSTAVAX regarding the adverse events was unknown. This is one of several reports from the same reporter. Additional information has been requested.
pt fell to floor approx 4min p/vax;when spoken to turned on side & began crying;pale w/warm, moist skin (room very moist w/hot);no further problems/mom;
HORRIBLE BODY PAIN; FEEL LIKE SHIT; FEVER; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 01-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  No concomitant medications were reported. On APR-2021, the subject experienced horrible body pain. On APR-2021, the subject experienced fever. On APR-2021, the subject experienced feel like shit. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the horrible body pain, fever and feel like shit was not reported. This report was non-serious.
pain at injection site 3-4 days after 1st dose; Patient did return for dose #2.; This case was reported by a consumer and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. On an unknown date, less than a week after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced injection site pain and incomplete course of vaccination. On an unknown date, the outcome of the injection site pain and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.  Additional details were provided as follows The age at vaccination not provided. The Shingrix vaccine administered about 2 months ago and experienced pain at injection site 3-4 days after 1st dose. The patient did return for dose 2 which led to incomplete course of vaccination. For tolerances of 2nd dose of Shingrix, refer case US2019AMR225546.
I have had a Slight headach since my second shot. Fast head movement or blood pressure increase from workouting causes pain to the front right loeb. Brain Swelling? Doctor gave me MethyLPEDNISolone 6 days. I day 3 80% of the pain/ issues seem to decrease. Felt better/ I was able to workout. Few days after treatment I am back to the same head pain.
Chest pain/Heart attack symptoms; Patient did not seem himself; Fatal heart attack; Shortness of breath; Pressure in his jaw; Stabbing pain in his back; Headache; This spontaneous case was reported by a patient family member or friend and describes the occurrence of MYOCARDIAL INFARCTION (Fatal heart attack), CHEST PAIN (Chest pain/Heart attack symptoms), DYSPNOEA (Shortness of breath), JOINT STIFFNESS (Pressure in his jaw), BACK PAIN (Stabbing pain in his back) and HEADACHE (Headache) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026C21A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID], AMLODIPINE and LOSARTAN for an unknown indication.   On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-May-2021, the patient experienced CHEST PAIN (Chest pain/Heart attack symptoms) (seriousness criterion hospitalization). On 24-May-2021, the patient experienced DYSPNOEA (Shortness of breath) (seriousness criterion hospitalization), JOINT STIFFNESS (Pressure in his jaw) (seriousness criterion hospitalization), BACK PAIN (Stabbing pain in his back) (seriousness criterion hospitalization) and HEADACHE (Headache) (seriousness criterion hospitalization). On 29-May-2021, the patient experienced MYOCARDIAL INFARCTION (Fatal heart attack) (seriousness criteria death and medically significant). On an unknown date, the patient experienced FEELING ABNORMAL (Patient did not seem himself). The patient was hospitalized from 24-May-2021 to 26-May-2021 due to CHEST PAIN. The patient died on 29-May-2021. The reported cause of death was fatal heart attack. It is unknown if an autopsy was performed. At the time of death, CHEST PAIN (Chest pain/Heart attack symptoms), DYSPNOEA (Shortness of breath), JOINT STIFFNESS (Pressure in his jaw), BACK PAIN (Stabbing pain in his back), HEADACHE (Headache) and FEELING ABNORMAL (Patient did not seem himself) outcome was unknown.            Treatment information was not provided.  This is a case of a 64 yo Male who died of a Myocardial Infarction 7 days after receiving the second dose. Very limited information regarding these events have been provided at this time. Patient's symptoms of jaw pain, pressure I his head and chest pain prior to vaccination may be a confounding factor to the events. No further information is expected.   This case was linked to MOD-2021-287620 (Patient Link).; Sender's Comments: This is a case of a 64 yo Male who died of a Myocardial Infarction 7 days after receiving the second dose. Very limited information regarding these events have been provided at this time. Patient's symptoms of jaw pain, pressure I his head and chest pain prior to vaccination may be a confounding factor to the events. No further information is expected.; Reported Cause(s) of Death: Fatal Heart attack
heart flutters; chills; This is a spontaneous report from a contactable consumer (patient) via medical information team. A 38-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection) via an unspecified route of administration on an unknown date in Mar2021 as single dose for covid-19 immunisation.  The patient's medical history and concomitant medications were not reported. On an unknown date, the patient reported that she was fine yesterday but today she was experiencing chills and what feels like heart flutters that come and go. The patient experienced heart flutters and chills. The outcome of the events was unknown.  Information about batch/lot no has been requested.
Slept for 3 hours. Headache. Horrific body ache, metallic taste in mouth. Tired.
7/18/06 gave immunization, 7/21/06 developed wheals on face, stomach, and back. Also raised red knot right deltoid at site where DTaP was given.
SWELLING, REDNESS, FEVER UPPER LEFT ARM. HER DR RECOMMENDED TYLENOL AND MADE HER APPT FOR 10/5/18 AT 1:30 PM.
For his first and second dose, He was eligible for the first and second dose while and so he got a second first and second dose there; For his first and second dose, He was eligible for the first and second dose  and so he got a second first and second dose there; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 4 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, single), administration date: Feb2021, for covid-19 immunization; Bnt162b2 (Dose 2, single), administration date: Feb2021, for covid-19 immunization; Bnt162b2 (Dose 3 (Booster), single), for covid-19 immunization. The following information was reported: OFF LABEL USE (non-serious), IMMUNISATION (non-serious), outcome "unknown" and all described as "For his first and second dose. He was eligible for the first and second dose and so he got a second first and second dose there".  Additional information: Patient got his first and second doses in Feb but had to repeat the vaccine. He was calling now to see if it was ok to not get the booster dose.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
This is a spontaneous report from a contactable consumer. A 18-year-old female patient (reporter friend's daughter) received a single dose of TRUMENBA on 09Aug2015. Concomitant medications and medical history were not reported. In Aug2015 (unknown if 09Aug2015 or 10Aug2015) the patient was having headache and neck pain. Subsequently, the family contacted the physician who advised them to give her TYLENOL to manage the symptoms. Outcome was unknown. Follow-up (09Oct2015): Follow-up attempts completed. No further information expected. Follow-up (16Oct2015): New information from the same contactable consumer includes: reporter type detail. Follow-up attempts completed. No further information expected.
ACUTE HYPOXEMIC RESPIRATORY FAILURE 9/12/2021 BLADDER CANCER, UNSPECIFIED SITE HYPOVOLEMIC SHOCK 9/12/2021 BLADDER CANCER, UNSPECIFIED SITE ACUTE HYPOXEMIC RESPIRATORY FAILURE 9/12/2021 BLADDER CANCER, UNSPECIFIED SITE HYPOVOLEMIC SHOCK 9/12/2021 BLADDER CANCER, UNSPECIFIED SITE ACUTE HYPOXEMIC RESPIRATORY FAILURE 9/12/2021 SYNCOPE HYPOVOLEMIC SHOCK 9/12/2021 SYNCOPE
Mild breathing difficulty at night before bedtime for a short while; Sore arm, body aches were mild; Sore arm, body aches were mild; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 08May2021 at 08:15 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified vitamins for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 17Apr2021 at 15:15 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. On 08May2021 at 21:45, the patient experienced mild breathing difficulty at night before bedtime for a short while around 21:45. Used essential oil to help breathing around 22:30 and the problem went away in the night. This morning (at the time of this report) woke at 07:00 and was totally fine. Took vitamins 3 hours after vaccine so all other side effects sore arm, body aches were mild. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events that included unspecified vitamins and essential oil. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events mild breathing difficulty at night before bedtime for a short while, sore arm, body aches were mild was resolved on an unknown date in May2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Exactly 4 days after receiving the vaccine I experienced intense stiffness of muscles and joints from neck to ankles.  I struggled to get up from sitting and then could barely walk until I was moving for a short while; then it was easier to walk but with the pain of the sore muscle/joint feeling.  It felt like I had been beat up, especially in my upper torso front and back.  It stayed the same until approximately 3:00 a.m.  on the second day.  i noticed the pain, stiffness, and difficulty moving was getting better.  It gradually continued to get better for the next 24 hours until completely gone.  My calf muscles were the last to return to normal.
At approximately 0845 the employee was vaccinated in the left arm with their 2nd Moderna vaccination. At approximately 0905 the employee began complaining of feeling slightly lightheaded. Denies any nausea, shortness of breath, no apparent rash, or itching. Called supervisor at approximately 0905 unable to reach. Approximately 0905 vital signs 98% O2, 97 pulse, 142/98 BP. Employee reports history of high blood pressure that is controlled with medication. At approximately 0910 called supervisor was able to report possible reaction to vaccine. Ordered to observe the employee. At approximately 0923 supervisor calls back and orders postural blood pressure check and to encourage employee to go home and consult with primary care physician. At approximately 0924. Employee denies any symptoms, reports feeling fine. Unable to perform laying check due to no bed, at approximately 0930 sitting 110/90, 97% O2, 98 pulse, 0935 standing 112/90, 100 pulse, 98% O2. At approximately 0938 employee departed clinic for home after reporting feeling fine. Employee was asked if he was ok to drive and they reported they were fine.
excessive hair loss on lower extremities (outer part of legs & lt side & back of head;hair has had odor that cant be washed out;doesn't subside w/shampoo-very strong;high temp @ noc only;
Hives (covered entire body), wheezing following vaccinations. Initial sats 90% RA, RR 40, tight chest alert/interactive. Gave 25mg Benadryl PO, 0.25mg, IM Epi, Albuterol nebulizer 1 time. Sat 97% RA. Sent by ambulance to ED for further management.
Chills, fever, headache, muscle aches, vomiting, tiredness  Started at 10pm Alleviated with Advil to dull headaches and body aches
I felt off with my head. I got headaches and dizziness. Over the next couple of days the headaches and dizziness got worse.  I had pain and dizziness seemed to emanate from the back of the head. There was a great deal of fatigue and nausea.  Experienced heaviness in chest. I sought medical attention after 48 hours.
Muscle aches, chills, woke up covered in sweat,  very tired and lethargic, nauseous
Patient had shot on 11/02/06. Afebrile left arm swollen 11-3-06.  Patient went to ER diagnosed with cellulitis.  KEFLEX given three times a day for 7 days.  11/-7-06 patient came to our office no swelling, no redness noted.
fever 99.9 nausea headache muscle cramping disorientation pain and puffiness at injection site
Patient came in with a history of mild dementia, confusion, temp 103.3, cough and congestion no vomiting or gi symptoms. Diagnoses: Acute Covid and UTI.
Serious incident of Microscopic Colitis beginning 12 days after the vaccine on 08/12/21 which continues. today after being prescribed and taking MethylPrednisolone.  I have a history of Microscopic Colitis but never had a case this bad or that last this long, especially when treated with a prescription.